Biotech Values

[dewophile]

I am not partial to either. Both have immense potential, but both very high risk. Personally I can't invest large dollars until I see the lead drug is not too immunogenic given the low sequence homology to native protein. That would be a deal breaker for the entire platform, although the ability to dose the antagonist orally might still be viable (I think immunogenicity risk is low, but still..)

clearly nl-201 is going to dictate the success of the company near term, but given the immense commercial opportunity in inflammation it wouldn't surprise me to hear that they partner the antagonist even before it enters the clinic (Merck for example paid nearly 2B for Pandion earlier this year for their IL-2 antagonist after only phase 1 safety data was available )